WO2001064659A2 - Derives d'indane - Google Patents

Derives d'indane Download PDF

Info

Publication number
WO2001064659A2
WO2001064659A2 PCT/GB2001/000844 GB0100844W WO0164659A2 WO 2001064659 A2 WO2001064659 A2 WO 2001064659A2 GB 0100844 W GB0100844 W GB 0100844W WO 0164659 A2 WO0164659 A2 WO 0164659A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
aryl
compounds
compound according
Prior art date
Application number
PCT/GB2001/000844
Other languages
English (en)
Other versions
WO2001064659A3 (fr
Inventor
Garry Fenton
Clive Mccarthy
Robert Edward Mackenzie
Andrew David Morley
Original Assignee
Aventis Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Limited filed Critical Aventis Pharma Limited
Priority to IL15072401A priority Critical patent/IL150724A0/xx
Priority to DE60105771T priority patent/DE60105771T2/de
Priority to AT01907923T priority patent/ATE277023T1/de
Priority to CA2401441A priority patent/CA2401441C/fr
Priority to EP01907923A priority patent/EP1259495B1/fr
Priority to AU35790/01A priority patent/AU3579001A/en
Priority to MXPA02008375A priority patent/MXPA02008375A/es
Priority to JP2001563500A priority patent/JP5021133B2/ja
Publication of WO2001064659A2 publication Critical patent/WO2001064659A2/fr
Publication of WO2001064659A3 publication Critical patent/WO2001064659A3/fr
Priority to US10/229,592 priority patent/US6762199B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Definitions

  • This invention is directed to indane derivatives, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of cell adhesion.
  • Cell adhesion is a process by which cells associate with each other, migrate towards a specific target or localise within the extra-cellular matrix.
  • Many of the cell-cell and cell-extracellular matrix interactions are mediated by protein ligands (e.g. fibronectin, VCAM-1 and vitronectin) and their integrin receptors [e.g. ⁇ 5 ⁇ l (VLA-5), ⁇ 4 ⁇ l (VLA-4) and ⁇ V ⁇ 3].
  • protein ligands e.g. fibronectin, VCAM-1 and vitronectin
  • VLA-5 integrin receptors
  • VLA-4 integrin receptors
  • Recent studies have shown these interactions to play an important part in many physiological (e.g. embryonic development and wound healing) and pathological conditions (e.g. tumour-cell invasion and metastasis, inflammation, atherosclerosis and autoimmune disease).
  • proteins serve as ligands for integrin receptors.
  • the proteins recognised by integrins fall into one of three classes: extracellular matrix proteins, plasma proteins and cell surface proteins.
  • Extracellular matrix proteins such as collagen fibronectin, fibrinogen, laminin, thrombospondin and vitronectin bind to a number of integrins.
  • Many of the adhesive proteins also circulate in plasma and bind to activated blood cells. Additional components in plasma that are ligands for integrins include fibrinogen and factor X.
  • Ig-like cell adhesion molecule Ig-like cell adhesion molecule
  • VCAM-1 vascular cell adhesion molecule
  • Integrins are heterodimeric cell surface receptors consisting of two subunits called ⁇ and ⁇ .
  • ⁇ -subunits There are at least fifteen different ⁇ -subunits ( ⁇ l- ⁇ 9, ⁇ -L, ⁇ -M, ⁇ -X, ⁇ -IIb, ⁇ -V and ⁇ -E) and at least seven different ⁇ ( ⁇ l- ⁇ 7) subunits.
  • the integrin family can be subdivided into classes based on the ⁇ subunits, which can be associated with one or more ⁇ -subunits.
  • the most widely distributed integrins belong to the ⁇ l class, also known as the very late antigens (VLA).
  • the second class of integrins are leukocyte specific receptors and consist of one of three ⁇ -subunits ( ⁇ -L, ⁇ -M or ⁇ -X) complexed with the ⁇ 2 protein.
  • the cytoadhesins ⁇ -IIb ⁇ 3 and ⁇ -V ⁇ 3, constitute the third class of integrins.
  • the present invention principally relates to agents which modulate the interaction of the iigand VCAM-1 with its integrin receptor ⁇ 4 ⁇ l (VLA-4), which is expressed on numerous hematopoietic cells and established cell lines, including hematopoietic precursors, peripheral and cytotoxic T lymphocytes, B lymphocytes, monocytes, thymocytes and eosinophils.
  • VLA-4 integrin receptor ⁇ 4 ⁇ l
  • the integrin ⁇ 4 ⁇ l mediates both cell-cell and cell-matrix interactions.
  • Cells expressing ⁇ 4 ⁇ l bind to the carboxy-terminal cell binding domain (CS-1) of the extracellular matrix protein fibronectin, to the cytokine-inducible endothelial cell surface protein VCAM-1, and to each other to promote homotypic aggregation.
  • CS-1 carboxy-terminal cell binding domain
  • VCAM-1 cytokine-inducible endothelial cell surface protein
  • the expression of VCAM-1 by endothelial cells is upregulated by proinflammatory cytokines such as INF- ⁇ , T F- ⁇ , IL-l ⁇ and IL-4.
  • ⁇ 4 ⁇ l mediated cell adhesion is important in numerous physiological processes, including T-cell proliferation, B-cell localisation to germinal centres, and adhesion of activated T-cells and eosinophils to endothelial cells.
  • Evidence for the involvement of VLA-4/VCAM-1 interaction in various disease processes such as melanoma cell division in metastasis, T-cell infiltration of synovial membranes in rheumatoid arthritis, autoimmune diabetes, colitis and leukocyte penetration of the blood-brain barrier in experimental autoimmune encephalomyelitis, atherosclerosis, peripheral vascular disease, cardiovascular disease and multiple sclerosis, has been accumulated by investigating the role of the peptide CS-1 (the variable region of fibronectin to which ⁇ 4 ⁇ l binds via the sequence Leu-Asp-Val) and antibodies specific for VLA-4 or VCAM-1 in various in vitro and in vivo experimental models of inflammation.
  • peptide CS-1 the variable region of fibronectin
  • the present invention is directed to compounds of general formula (I):-
  • R! represents aryl, heteroaryl or a group R 3 -L 2 -Ar*-L 3 -;
  • R 2 represents hydrogen or lower alkyl;
  • R 3 represents aryl or heteroaryl;
  • R represents alkyl, alkenyl, alkynyl, aryl, arylalkyl, ar lalkenyl, arylalkynyl, cycloalkyl, cycloalkylalkvl, cycloalkylalkenvl, cycloalkylalkynyl, cycloalkenyl, cycloalkenvlalkyl, heteroar l, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocycloalkyl or heterocycloalkvlalkvl;
  • R" is hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;
  • R' is hydrogen, R ⁇ or alkyl substituted with alkoxy, cycloalkyl, hydroxy, mercapto, alkvlthio or -NY 3 Y 4 ;
  • R° is hydrogen or lower alkyl
  • R! represents Cj. ⁇ alkylene, optionally substituted by R 4 ;
  • R* 2 is an alkvlene chain, an alkenylene chain, or an alkynylene chain
  • R ⁇ 3 is alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroary lalkyl, heterocycloalkyl or heterocycloalkylalkyl;
  • Arl represents an optionally substituted saturated, partially saturated or fully unsaturated 8 to 10 membered bicyclic ring system containing at least one heteroatom selected from O, S or N;
  • Ar 2 is arylene or heteroaryldiyl;
  • L 3 represents an alkylene, alkenylene or alkynylene chain
  • L 4 and L" each independently represent a direct bond or an alkylene chain
  • L ⁇ represents a cycloalkylene or an indanylene
  • Y is carboxy or an acid bioisostere
  • Z is O or S;
  • m is an integer 1 or 2;
  • n is zero or an integer 1 or 2;
  • p is zero or an integer 1 to 4;
  • o R 2 the group R i C i N I is attached to the benzene ring of the indane system and the group L Y is attached to either ring of the indane system; and any aryl or heteroaryl moieties present as a group or part of a group may be optionally substituted; but excluding compounds where an oxygen, nitrogen or sulfur atom is attached directly to a carbon carbon multiple bond of an alkenylene, alkynylene or cycloalkenylene residue; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and
  • the term "compounds of the invention”, and equivalent expressions, are meant to embrace compounds of general formula (I) as hereinbefore described, which expression includes the prodrugs, protected derivatives of compounds of formula (I) containing one or more acidic functional groups and/or amino-acid side chains, the pharmaceutically acceptable salts, and the solvates, e.g. hydrates, where the context so permits.
  • reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits.
  • particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and it is not intended to exclude other instances when the context so permits.
  • “Patient” includes both human and other mammals.
  • “Acid bioisostere” means a group which has chemical and physical similarities producing broadly similar biological properties to a carboxy group (see Lipinski, Annual Reports in Medicinal Chemistry, 1986, 21, page 283 "Bioisosterism In Drug Design” ; Yun, Hvvahak Sekye, 1993, 33, pages 576-579 "Application Of Bioisosterism To New Drug Design”; Zhao, Huaxue Tongbao, 1995, pages 34-38 "Bioisosteric Replacement And Development Of Lead Compounds In Drug Design” ; Graham, Theochem, 1995, 343, pages 105-109 "Theoretical Studies Applied To Drug Design:ab initio Electronic Distributions In Bioisosteres”).
  • Acidic functional group means a group with an acidic hydrogen within it.
  • the “protected derivatives” are those where the acidic hydrogen atom has been replaced with a suitable protecting group.
  • suitable protecting groups see T.W. Greene and P.G.M.Wuts in "Protective Groups in Organic Chemistry” John Wiley and Sons, 1991.
  • Exemplary acidic functional groups include carboxyl (and acid bioisosteres), hydroxy, mercapto and imidazole.
  • Exemplary protected derivatives include esters of carboxy groups (i.e. -C0 2 R* 3 ), ethers of hydroxy groups (i.e. -OR* 3 ), thioethers of mercapto groups (i.e. -SR 3 ), and N-benzyl derivatives of imidazoles.
  • Acyl means an H-CO- or alkyl-CO- group in which the alkyl group is as described herein.
  • acylamino is an acyl-NH- group wherein acyl is as defined herein.
  • Alkenyl means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain.
  • Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear chain; here a linear alkenyl chain.
  • “Lower alkenyl” means about 2 to about 4 carbon atoms in the chain which may be straight or branched.
  • alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexylbutenyl and decenyl.
  • Alkenylene means an aliphatic bivalent radical derived from a straight or branched alkenyl group, in w hich the alkenyl group is as described herein.
  • Exemplary alkenylene radicals include vinylene and propylene.
  • Alkoxy means an alkyl-O- group in which the alkyl group is as described herein.
  • exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and heptoxy.
  • Alkoxycarbonyl means an alkyl-O-CO- group in which the alkyl group is as described herein.
  • exemplary alkoxycarbonyl groups include methoxy- and ethoxycarbonyl.
  • Alkyl means, unless other ise specified, an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 15 carbon atoms in the chain optionally substituted by alkoxy or by one or more halogen atoms. Particular alkyl groups have from 1 to about 6 carbon atoms.
  • “Lower alkyl” as a group or part of a lower alkoxy, lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl group means unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 4 carbon atoms in the chain.
  • Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, 3-pentyl, heptyl, octyl, nonyl, decyl and dodecyl.
  • Alkylene means an aliphatic bivalent radical derived from a straight or branched alkyl group, in which the alkyl group is as described herein.
  • exemplary alkylene radicals include methylene, ethylene and trimethylene.
  • Alkylenedioxy means an -O-alkyl-O- group in which the alkyl group is as defined above.
  • exemplary alkylenedioxy groups include methylenedioxy and eth lenedioxy.
  • Alkylsulfinyl means an alkyl-SO- group in which the alkyl group is as previously described.
  • Preferred alkylsulfinyl groups are those in which the alkyl group is C ⁇ _4alky .
  • Alkylthio means an alkyl-S- group in which the alkyl group is as previously described.
  • exemplary alkylthio groups include methylthio, ethylthio, isopropylthio and heptylthio.
  • Alkynyl means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, i-butynyl, 3-methylbut-2-ynyl, and n-pentynyl.
  • Alkynylene means an aliphatic bivalent radical derived from a C 2 _6alkynyl group.
  • exemplary alkynylene radicals include ethynylene and propynylene.
  • amino acid side chains means the substituent found on the carbon between the amino and carboxy groups in ⁇ -amino acids.
  • protected derivatives of amino acid side chains, see T.W. Greene and P.G.M.Wuts in “Protective Groups in Organic Chemistry " John Wiley and Sons, 1991.
  • Aroyl means an aryl-CO- group in which the aryl group is as described herein.
  • Exemplary aroyl groups include benzoyl and 1- and 2-naphthoyl.
  • Aroylamino is an aroyl-NH- group wherein aroyl is as previously defined.
  • Aryl as a group or part of a group denotes: (i) an optionally substituted monocyclic or multicyclic aromatic carbocyclic moiety of about 6 to about 14 carbon atoms, such as phenyl or naphthyl; or (ii) an optionally substituted partially saturated multicyclic aromatic carbocyclic moiety in which an aryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure, such as a tetrahydronaphthyl, indenyl or indanyl ring.
  • Aryl groups may be substituted with one or more aryl group substituents which may be the same or different, where "aryl group substituent" includes, for example, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy, cyano, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, hydroxy, nitro, trifluoromethyl, -NY*Y 2 , -CONY*Y 2 , -S0 2 N ⁇ ! ⁇
  • Arylalkenyl means an aryl-alkenyl- group in which the aryl and alkenyl are as previously described. Preferred arylalkeny s contain a lower alkenyl moiety. Exemplary arylalkenyl groups include styryl and phenylallyl.
  • Arylalkyl means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a C j _4alkyl moiety. Exemplary arylalkyl groups include benzyl, 2-phenethyl and naphthlenemethyl.
  • Arylalkyloxy means an arylalkyl-O- group in which the arylalkyl groups is as previously described.
  • exemplary arylalkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.
  • Arylalkyloxycarbonyl means an arylalkyl-O-CO- group in which the arylalkyl groups is as previously described.
  • An exemplar arylalkyloxycarbonyl group is benzyloxycarbonyl.
  • Arylalkylthio means an arylalkyl-S- group in which the arylalkyl group is as previously described.
  • An exemplary arylalkylthio group is benzylthio.
  • Arylalkynyl means an aryl-alkynyl- group in which the aryl and alkynyl are as previously described.
  • exemplary arylalkynyl groups include phenylethynyl and 3-phenylbut-2-ynyl.
  • Arylene means an optionally substituted bivalent radical derived from an aryl group.
  • exemplary arylene groups include optionally substituted phenylene, naphthylene and indanylene.
  • Aryloxy means an aryl-O- group in which the aryl group is as previously described.
  • exemplary aryloxy groups include optionally substituted phenoxy and naphthoxy.
  • exemplary aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.
  • Arylsulfinyl means an aryl-SO- group in which the aryl group is as previously described.
  • Arylsulfonyl means an aryl-S0 2 - group in which the aryl group is as previously described.
  • Arylthio means an aryl-S- group in which the aryl group is as previously described.
  • exemplary arylthio groups include phenylthio and naphthylthio.
  • Azaheteroaryl means an aromatic carbocyclic moiety of about 5 to about 10 ring members in which one of the ring members is nitrogen and the other ring members are chosen from carbon, oxygen, sulfur, or nitrogen.
  • Examples of azaheteroaryl groups include benzimidazolyl, imidazolyl, isoquinolinyl, isoxazolyl, pyrazolopyrimidinyl, pyridyl, pyrimidinyl, quinolinyl, quinazolinyl and thiazolyl.
  • Azaheteroaryldiyl means an optionally substituted bivalent radical derived from a heteroaryl group.
  • Cyclic amine means a 3 to 8 membered monocyclic cycloalkyl ring system where one of the ring carbon atoms is replaced by nitrogen and which (i) may optionally contain an additional heteroatom selected from O, S or NY" (where Y" is hydrogen, alkyl, arylalkyl, and aryl) and (ii) may be fused to additional aryl or heteroaryl ring to form a bicyclic ring system.
  • Exemplary cyclic amines include pyrrolidine, piperidine, morpholine, piperazine, indoline and pyrindoline.
  • Cycloalkenyl means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having about 3 to about 10 carbon atoms.
  • Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl or cycloheptenyl.
  • Cycloalkenvlalkyl means a cycloalkenyl-alkyl- group in w hich the cycloalkenyl and alkyl moieties are as previously described. Exemplary cycloalkenvlalkyl groups include cyclopentenylmethyl, cyclohexenylmethyl or cycloheptenylmethyl.
  • Cycloalkenylene means a bivalent radical derived from an unsaturated monocyclic hydrocarbon of about 3 to about 10 carbon atoms by removing a hydrogen atom from each of two different carbon atoms of the ring. Exemplary cycloalkenylene radicals include cyclopentenylene and cyclohexenylene.
  • Cycloalkyl means a saturated monocyclic or bicyclic ring system of about 3 to about 10 carbon atoms optionally substituted by oxo.
  • Exemplary monocyclic cycloalkyl rings include C .gcycloalkyl rings such as cyclopropy , cyclopentyl, cyclohexyl and cycloheptyl.
  • Cycloalkylalkenyl means a cycloalkyl-alkenyl- group in which the cycloalkyl and alkenyl moieties are as previously described.
  • Exemplary monocyclic cycloalkylalkenyl groups include cyclopentylvinylene and cyclohexylvinylene.
  • Cycloalkylalkyl means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described.
  • Exemplary monocyclic cycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.
  • Cycloalkylalkynyl means a cycloalkyl-alkynyl- group in which the cycloalkyl and alkynyl moieties are as previously described.
  • Exemplary monocyclic cycloalkylalkynyl groups include cyclopropylethynyl, cyclopentylethynyl and cyclohexylethynyl.
  • Cvcloalkvlene means a bivalent radical derived from a saturated monocyclic hydrocarbon of about 3 to about 10 carbon atoms by removing a hydrogen atom from each of two different carbon atoms of the ring.
  • exemplary cycloalkenylene radicals include cyclopropylene, cyclopentylene and cyclohexylene.
  • Halo or halogen means fluoro, chloro, bromo, or iodo. Preferred are fluoro or chloro.
  • exemplary groups include pyridylcarbonyl.
  • Heteroaroylamino means a heteroaroyl-NH- group in which the heteroaryl moiety are as previously described.
  • Heteroaryl as a group or part of a group denotes: (i) an optionally substituted aromatic monocyclic or multicyclic organic moiety of about 5 to about 10 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulfur (examples of such groups include benzimidazolyl, benzthiazolyl, furyl, imidazolyl, indolyl, indolizinyl, isoxazolyl, isoquinolinyl, isothiazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, 1,3,4-thi
  • Heteroarylalkenyl means a heteroaryl-alkenyl- group in which the heteroaryl and alkenyl moieties are as previously described. Preferred heteroarylalkenyl groups contain a lower alkenyl moiety. Exemplary heteroarylalkenyl groups include pyridylethenyl and pyridylallyl.
  • Heteroarylalkyl means a heteroaryl-alkyl- group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a C ⁇ _4alkyl moiety.
  • heteroarylalkyl groups include pyridylmethyl.
  • Heteroarylalkyloxy means an heteroarylalkyl-O- group in which the heteroarylalkyl group is as previously described.
  • exemplary heteroaryloxy groups include optionally substituted pyridylmethoxy.
  • Heteroarylalkynyl means a heteroaryl-alkynyl- group in which the heteroaryl and alkynyl moieties are as previously described.
  • exemplary heteroarylalkenyl groups include pyridylethynyl and 3-pyridylbut-2-ynyl.
  • Heteroaryldiyl means a bivalent radical derived from an aromatic monocyclic or multicyclic organic moiety of about 5 to about 10 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulfur, and optionally substituted by one or more "aryl group substituents" as defined above.
  • Heteroaryloxy means an heteroaryl-O- group in which the heteroaryl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridyloxy.
  • Heterocycloalkyl means: (i) a cycloalkyl group of about 3 to 7 ring members which contains one or more heteroatoms selected from O, S or NY 3 and which ma ⁇ optionally be substituted by oxo; (ii) an optionally substituted partially saturated multicyclic heterocarbocyclic moiety in which an aryl (or heteroaryl ring) and a heterocycloalkyl group are fused together to form a cyclic structure (examples of such groups include chroman l, dihydrobenzofuranyl, indolinyl and pyrindolinyl groups).
  • Heterocycloalkylalkyl means a heterocycloalkyl-alkyl- group in hich the heterocycloalkyl and alkyl moieties are as previously described.
  • Heterocycloalkylene means a bivalent radical derived from a saturated monocyclic hydrocarbon of about 5 to about 7 atoms, which contains one or more heteroatoms selected from
  • O, S or NY and is optionally substituted by oxo, by removing a hydrogen atom from each of two different carbon atoms of the ring, or when NY > is NH by removing a hydrogen atom from one carbon atom of the ring and a hydrogen atom from the NH, or when the ring contains two NY" heteroatoms and NY" is NH by removing a hydrogen atom from both nitrogen atoms.
  • Prodrug means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of formula (I), including N-oxides thereof.
  • an ester of a compound of formula (I) containing a hydroxy group may be convertible by hydrolysis in vivo to the parent molecule.
  • an ester of a compound of formula (I) containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule.
  • Suitable esters of compounds of formula (I) containing a hydroxy group are for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis- ⁇ -hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates.
  • Suitable esters of compounds of formula (I) containing a carboxy group are for example those described by F.J.Leinweber, Drug Metab. Res., 1987, 18, page 379.
  • Suitable esters of compounds of formula (I) containing both a carboxy group and a hydroxy group within the moiety -L ⁇ -Y include lactones, formed by loss of water between said carboxy and hydroxy groups.
  • lactones include caprolactones and butyrolactones.
  • esters of compounds of formula (I) containing a hydroxy group may be formed from acid moieties selected from those described by Bundgaard et. al., J. Med. Chem., 1989, 32 , page 2503-2507, and include substituted (aminomethyl)-benzoates, for example dialkylamino-methylbenzoates in which the two alkyl groups may be joined together and/or interrupted by an oxygen atom or by an optionally substituted nitrogen atom, e.g. an alkylated nitrogen atom, more especially (morpholino-methyl)benzoates, e.g. 3- or 4-(morpholinomethyl)-benzoates, and (4-alkylpiperazin-l-yl)benzoates, e.g. 3- or 4-(4-alkylpiperazin-l-yl)benzoates.
  • substituted (aminomethyl)-benzoates for example dialkylamino-methylbenzoates in which the two alkyl groups may be joined together and/or interrupted by
  • base addition salts may be formed and are simply a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free acid form.
  • the bases which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose cations are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the cations.
  • Pharmaceutically acceptable salts including those derived from alkali and alkaline earth metal salts, within the scope of the invention include those derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl- glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine,
  • acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the anions.
  • compositions are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures.
  • Pharmaceutically acceptable salts within the scope of the invention include those derived from mineral acids and organic acids, and include hydrohalides, e.g.
  • salts of compounds of the invention are useful for the purposes of purification of the compounds, for example by exploitation of the solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those skilled in the art.
  • R! may particularly represent optionally substituted aryl, such as optionally substituted phenyl
  • optional substituents include one or more groups (e.g. 1 or 2) selected from aryloxy, cyano, halo (e.g. chloro or fluoro), lower alkoxy (e.g. methoxy), lower alkyl (e.g. methyl), nitro and perfluoroloweralkyl (e.g. trifluoromethyl)].
  • R* especially represents substituted phenyl selected from 2-chlorophenyl, 5-chloro-2-cyanophenyl, 2-chloro-6-methylphenyl, 2,6-dichlorophenyl, 2,6-difluorophenyl, 4-fluoro-2-trifluoromethyl, 2-methyl-4-nitrophenyl, 2-methyl-5-nitrophenyl, 2-nitrophenyl, 3-nitrophenyl or 2-phenoxyphenyl.
  • R! especially represents an optionally substituted azaheteroary l selected from quinolin-4-yl, isoquinolin-2-yl, 2,4-pyridin-3-yl, 2,6-dimethyl-4-trifluoromethylpyridin-3-yl, 4-trifluoromethylpyridin3-yl, 2-phenyl-4-methyl-l ,2,3-triazol-5-yl, 3,5-dimethylisoxazol-4-yl, 2,7-dimethylpyrazolo-[l,5-a]pyrimidin-6-yl, 2-isopropyl-4-methylthiazol-5-yl and 4-trifluoromethylpyrimidin-5-yl.
  • R! may also particularly represent a group R 3 -L 2 -Arl-L 3 - in which: R 3 and L 2 are as defined above; L 3 represents a straight or branched C j . ⁇ alkylene chain, more particularly a straight C ⁇ _4alkylene chain such as methylene or ethylene, preferably methylene and Ar is an 8 to 10
  • membered bicyclic system is a 5 or 6 membered
  • aryl group substituents as defined above [examples of particular aryl group substituents include C ⁇ _4alkyl (e.g. methyl or ethyl), C ⁇ _4alkoxy (e.g. methoxy), amino, halogen, hydroxy, Cj_4alkylthio, C ⁇ _4alkylsulfinyl, Ci ⁇ alkylsulfonyl, nitro or trifluoromethyl].
  • L 2 is preferably NH and R 3 is particularly optionally substituted aryl, such as monosubstituted or disubstituted phenyl, [examples of particular aryl group substituents include lower alkyl (e.g. methyl), lower alkoxy (e.g. methoxy), halo (e.g. fluoro or chloro) and Y*Y N- (e.g. dimethylamino)].
  • aryl such as monosubstituted or disubstituted phenyl
  • substituents include lower alkyl (e.g. methyl), lower alkoxy (e.g. methoxy), halo (e.g. fluoro or chloro) and Y*Y N- (e.g. dimethylamino)].
  • R 2 may particularly represent hydrogen.
  • R 2 may also particularly represent lower alkyl, (e.g. methyl).
  • L* may particularly represent an optionally substituted alkylene linkage (e.g. optionally substituted methylene, optionally substituted ethylene or optionally substituted propylene).
  • Preferred optional substituents include lower alkyl, aryl, heteroaryl, -ZH, -ZR* 3 ,
  • L 1 is
  • L* is a group C CH- — [where R* is
  • R 14 preferred embodiment L* is a group CH 2— C [where R* 4 is hydrogen or lower alk l (e.g.
  • L* may also particularly represent a -L 4 -L ⁇ -L°- linkage, in which L 4 and L" are independently a direct bond or alkylene (e.g. methylene) and L ⁇ is cvcloalkvlene, such as cyclopropylene or cyclopentylene, or indanylene.
  • L 4 and L" are independently a direct bond or alkylene (e.g. methylene) and L ⁇ is cvcloalkvlene, such as cyclopropylene or cyclopentylene, or indanylene.
  • Y may particularly represent carboxy.
  • a particular group of compounds of the invention are compounds of formula (la):-
  • R 2 , R 3 , L ⁇ , L 2 , L 3 and Y are as hereinbefore defined;
  • X is O or NR* 8 (where R ⁇ 8 is hydrogen or lower alkyl); and
  • R* 7 is hydrogen, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, ary sulfonyl, arylthio, carboxy, cyano, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, hydroxy, nitro, trifluoromethyl, -NY*Y
  • R 3 represents optionally substituted aryl, especially monosubstituted or disubstituted phenyl, are preferred.
  • Preferred optional substituents include lower alkyl (e.g. methyl), lower alkoxy (e.g. methoxy), halo (e.g. fluoro or chloro) and ⁇ l ⁇ 2 N-
  • R 3 especially represents phenyl substituted in at least the 2-position, for example by a C ⁇ alkyl group such as methyl.
  • R* 7 represents hydrogen, halo (e.g. chloro), lower alkyl (e.g. methyl or ethyl) or lower alkoxy (e.g. methoxy) are preferred.
  • L* represents an optionally substituted alkylene linkage (e.g. optionally substituted methylene, optionally substituted ethylene or optionally substituted propylene) are preferred.
  • L 1 is
  • L 1 is a group C CH — [where R 14 is
  • R 14 preferred embodiment L 1 is a group CH 2— C [where R 14 is hydrogen or lower alkyl (e.g.
  • L 1 represents a -L 4 -L ⁇ -L"- linkage, in which L 4 and L" are independently a direct bond or alkylene (e.g. methylene) and L ⁇ is cycloalkylene, such as cyclopropylene or cyclopentylene, or indanylene are also preferred.
  • a preferred group of compounds of the invention are compounds of formula (la) in which:- R 2 is hydrogen or lower alkyl (e.g. methyl); R 3 is optionally substituted phenyl (especially phenyl substituted in at least the 2-position, e.g. by C ⁇ alkyl); R 17 is hydrogen, chloro, C j ⁇ alkyl, or
  • L 1 is methylene
  • L 2 is NH
  • L 3 is a straight Cj_4alkylene chain, especially methylene
  • X is O
  • Y is carboxy; the group is attached at
  • the benzoxazole ring 6a position the nitrogen atom of the linkage is attached to the indane ring 5 or 6 position; and the -L*-Y group is attached to the indane ring 1 or 2 position; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. h ⁇ drates) of such compounds and their N-oxides and prodrugs.
  • Another preferred group of compounds of the invention are compounds of formula (la) in which:-R 2 is hydrogen or lower alkyl (e.g. methyl); R 3 is optionally substituted phenyl (especially phenyl substituted in at least the 2-position, e.g. by Chalky!); R 17 is hydrogen. chloro, C ⁇ _4alkyl, or C j _4alkoxy; L 1 is methylene; L 2 is NH; L 3 is a straight C ⁇ _4alkylene chain, especially methylene; X is NR 18 (especially NH); Y is carboxj ; the group
  • R 2 , R 3 , L , L 2 , L 3 and Y are as hereinbefore defined;
  • X is O or NR 18 (where R 8 is hydrogen or lower alkyl); and
  • R 17 is hydrogen, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy, cyano, halo, heteroaroyl, heteroary l, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, hydroxy, nitro, trifluoromethyl, -NY ⁇ Y 2
  • R 3 represents optionally substituted aryl, especially monosubstituted or disubstituted phenyl, are preferred.
  • Preferred optional substituents include lower alkyl (e.g. methyl), lower alkoxy (e.g. methoxy), halo (e.g. fluoro or chloro) and Y ⁇ Y 2 ⁇
  • R 3 especially represents phenyl substituted in at least the 2-position, for example by a C j _4alkyl group such as methyl.
  • R 17 represents hydrogen, halo (e.g. chloro), lower alkyl (e.g. methyl or ethyl) or lower alkoxy (e.g. methoxy) are preferred.
  • L 3 represents a straight or branched C j .galkylene chain, especially a straight C j _4alkylene chain, more especially methylene, are preferred.
  • L 1 represents an optionally substituted alkylene linkage (e.g. optionally substituted methylene, optionally substituted ethylene or optionally substituted propylene) are preferred.
  • Preferred optional substituents include lower alkyl, aryl, heteroaryl,
  • L 1 is a
  • R 1 hydrogen or lower alkyl
  • R 14 a group CH 2— C [where R 14 is hydrogen or lower alkyl (e.g. methyl) and R 1 " represents
  • a preferred group of compounds of the invention are compounds of formula (lb) in which:- R 2 is hydrogen or lower alkyl (e.g. methyl); R 3 is optionally substituted phenyl (especially phenyl substituted in at least the 2-position, e.g. by C ⁇ alkyl); R 17 is hydrogen, chloro, C ⁇ _4alkyl, or C ⁇ _4alkoxy; L is a CH — CH j — group particularly a CH CH- group, where R 1 ⁇
  • L 2 is NH;
  • L 3 is a straight or branched C j ⁇ alkylene chain,
  • Another preferred group of compounds of the invention are compounds of formula (lb) in which:- R 2 is hydrogen or lower alkyl (e.g. methyl); R 3 is optionally substituted phenyl (especially phenyl substituted in at least the 2-position, e.g. by C ⁇ _4alkyl); R 17 is hydrogen, chloro, C ⁇ _4alkyl, or C ⁇ _4alkoxy; L 1 is a CH— CH — group, particularly
  • L 2 is NH;
  • L 3 is a
  • R straight C ⁇ _4alkylene chain especially methylene
  • X is O
  • Y is carboxy
  • R 2 is hydrogen or lower alkyl (e.g. methyl);
  • R 3 is optionally substituted phenyl (especially phenyl substituted in at least the 2-position, e.g. by C ⁇ alkyl);
  • R 7 is hydrogen, chloro, C ⁇ _4alkyl, or C j _4alkoxy;
  • L is a CH — CH- — group particularly a CH CH ;
  • L 2 is NH;
  • L 3 is a straight C ⁇ _ 4 alkylene chain, especially methylene;
  • X is NR 8 (especially NH);
  • Y is carboxy; the group ed at the benzimidazole ring 5a or 6a position; the
  • R 2 is hydrogen or lower alkyl (e.g. methyl);
  • R 3 is optionally substituted phenyl (especially phenyl substituted in at least the 2-position, e.g. by C ⁇ alkyl);
  • R 17 is hydrogen, chloro, C ⁇ _4alkyl, or C j _4alkoxy;
  • L is a CH— CH — group, particularly
  • L 2 is NH
  • L 3 i is a straight C ⁇ _4alkylene chain, especially methylene
  • X is NR 18 (especially NH)
  • Y is carboxy;
  • N nitrogen atom of the j — linkage is attached to the indane ring 4 position;
  • -L ⁇ -Y group is attached to the indane ring 7 position: and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.
  • Particular compounds of the invention of formula 1(a) are selected from the compounds formed by joining the carbon atom (C*) of one of the fragments (Al to A36) shown in Table 1 to the nitrogen atom (N*) of one of the fragments (B5 to B12) shown in Table 2, and joining the carbon atom (C*) of one of the fragments (B5 to B12) shown in Table 2 to the carbon atom (C*) of one of the acidic fragments (Cl to C3) depicted in Table 3.
  • Particular compounds of the invention of formula 1(b) are selected from the compounds formed by joining the carbon atom (C*) of one of the fragments (Al to A36) shown in Table 1 to the nitrogen atom (N*) of one of the fragments (BI to B4) shown in Table 2, and joining the carbon atom (C*) of one of the fragments (BI to B4) shown in Table 2 to the carbon atom (C*) of one of the acidic fragments (C3 to C32) depicted in Table 3.
  • A29-B6-C1 A29-B6-C2 A29-B6-C3 A30-B6-C1 A30-B6-C2 A30-B6-C3
  • A1-B1-C15 A1-B1-C16 A1-B1-C17 A1-B1-C18 A1-B1-C19 A1-B1-C20
  • A3-B1-C15 A3-B1-C16 A3-B1-C17 A3-B1-C18 A3-B1-C19 A3-B1-C20
  • A5-B1-C15 A5-B1-C16 A5-B1-C17 A5-B1-C18 A5-B1-C19 A5-B1-C20
  • A6-B1-C15 A6-B1-C16 A6-B1-C17 A6-B1-C18 A6-B1-C19 A6-B1-C20
  • A10-B1-C9 A10-B1-C10 A10-B1-C11 A10-B1-C12 A10-B1-C13 A10-B1-C14
  • A10-B1-C15 A10-B1-C16 A10-B1-C17 A10-B1-C18 A10-B1-C19 A10-B1-C20
  • A11-B1-C15 A11-B1-C16 A11-B1-C17 A11-B1-C18 A1 1-B1-C19 A11-B1-C20
  • A12-B1-C15 A12-B1-C16 A12-B1-C17 A12-B1-C18 A12-B1-C19 A12-B1-C20
  • A13-B1-C15 A13-B1-C16 A13-B1-C17 A13-B1-C18 A13-B1-C19 A13-B1-C20
  • A14-B1-C15 A14-B1-C16 A14-B1-C17 A14-B1-C18 A14-B1-C19 A14-B1-C20
  • A15-B1-C15 A15-B1-C16 A15-B1-C17 A15-B1-C18 A15-B1-C19 A15-B1-C20
  • A16-B1-C15 A16-B1-C16 A16-B1-C17 A16-B1-C18 A16-B1-C19 A16-B1-C20
  • A17-B1-C15 A17-B1-C16 A17-B1-C17 A17-B1-C18 A17-B1-C19 A17-B1-C20
  • A29-B1-C15 A29-B1-C16 A29-B1-C17 A29-B1-C18 A29-B1-C19 A29-B1-C20
  • A30-B1-C15 A30-B1-C16 A30-B1-C17 A30-B1-C18 A30-B1-C19 A30-B1-C20
  • A31-B1-C15 A31-B1-C16 A31-B1-C17 A31-B1-C18 A31-B1-C19 A31-B1-C20
  • A32-B1-C15 A32-B1-C16 A32-B1-C17 A32-B1-C18 A32-B1-C19 A32-B1-C20
  • A33-B1-C15 A33-B1-C16 A33-B1-C17 A33-B1-C18 A33-B1-C19 A33-B1-C20
  • A34-B1-C15 A34-B1-C16 A34-B1-C17 A34-B1-C18 A34-B1-C19 A34-B1-C20
  • A35-B1-C15 A35-B1-C16; A35-B1-C17 A35-B1-C18 A35-B1-C19 A35-B1-C20
  • A36-B1-C15 A36-B1-C16 A36-B1-C17 A36-B1-C18 A36-B1-C19 A36-B1-C20
  • A14-B2-C15 A14-B2-C16 A14-B2-C17; A14-B2-C18; A14-B2-C19; A14-B2-C20;
  • A15-B2-C21 A15-B2-C22 A15-B2-C23; A15-B2-C24; A15-B2-C25; A15-B2-C26;
  • A16-B2-C15 A16-B2-C16 A16-B2-C17; A16-B2-C18; A16-B2-C19; A16-B2-C20;
  • A16-B2-C21 A16-B2-C22 A16-B2-C23; A16-B2-C24; A16-B2-C25; A16-B2-C26;
  • A17-B2-C15 A17-B2-C16 A17-B2-C17; A17-B2-C18; A17-B2-C19; A17-B2-C20;
  • A17-B2-C21 A17-B2-C22 A17-B2-C23; A17-B2-C24; A17-B2-C25; A17-B2-C26;
  • A18-B2-C15 A18-B2-C16 A18-B2-C17; A18-B2-C18; A18-B2-C19; A18-B2-C20;
  • A18-B2-C21 A18-B2-C22 A18-B2-C23; A18-B2-C24; A18-B2-C25; A18-B2-C26;
  • A19-B2-C15 A19-B2-C16 A19-B2-C17; A19-B2-C18; A19-B2-C19; A19-B2-C20;
  • A19-B2-C21 A19-B2-C22 A19-B2-C23; A19-B2-C24; A19-B2-C25; A19-B2-C26;
  • A20-B2-C15 A20-B2-C16 A20-B2-C17; A20-B2-C18; A20-B2-C19; A20-B2-C20;
  • A21-B2-C15 A21-B2-C16 A21-B2-C17; A21-B2-C18; A21-B2-C19; A21-B2-C20;
  • A22-B2-C15 A22-B2-C16 A22-B2-C17; A22-B2-C18; A22-B2-C19; A22-B2-C20;
  • A22-B2-C21 A22-B2-C22 A22-B2-C23; A22-B2-C24; A22-B2-C25; A22-B2-C26;
  • A23-B2-C15 A23-B2-C16 A23-B2-C17; A23-B2-C18; A23-B2-C19; A23-B2-C20;
  • A23-B2-C21 A23-B2-C22 A23-B2-C23; A23-B2-C24; A23-B2-C25; A23-B2-C26;
  • A25-B2-C15 A25-B2-C16; A25-B2-C17 A25-B2 C18; A25-B2 -C19; A25-B2-C20
  • A25-B2-C27 A25-B2-C28; A25-B2-C29 A25-B2 C30; A25-B2 -C31 ; A25-B2-C32
  • A26-B2-C15 A26-B2-C16; A26-B2-C17 A26-B2 C18; A26-B2 C19; A26-B2-C20
  • A27-B2-C15 A27-B2-C16; A27-B2-C17 A27-B2 -C18; A27-B2 C19 A27-B2-C20
  • A28-B2-C15 A28-B2-C16; A28-B2-C17 A28-B2 -C18; A28-B2 C19; A28-B2-C20
  • A29-B2-C15 A29-B2-C16; A29-B2-C17 A29-B2 ⁇ C18; A29-B2 C19; A29-B2-C20
  • A30-B2-C15 A30-B2-C16; A30-B2-C17 A30-B2 -C18; A30-B2 C19; A30-B2-C20
  • A31-B2-C15 A31-B2-C16; A31-B2-C17 A31-B2 C18; A31-B2 C19; A31-B2-C20
  • A32-B2-C15 A32-B2-C16; A32-B2-C17 A32-B2 C18; A32-B2 C19; A32-B2-C20
  • A33-B2-C15 A33-B2-C16; A33-B2-C17 A33-B2 C18; A33-B2 C19; A33-B2-C20
  • A34-B2-C15 A34-B2-C16; A34-B2-C17 A34-B2- C18; A34-B2 C19; A34-B2-C20
  • A1-B3-C15 A1-B3-C16 A1-B3-C17 A1-B3-C18 A1-B3-C19 A1-B3-C20
  • A3-B3-C15 A3-B3-C16 A3-B3-C17 A3-B3-C18 A3-B3-C19 A3-B3-C20
  • A10-B3-C9 A10-B3-C10 A10-B3-C11 A10-B3-C12 A10-B3-C13 A10-B3-C14
  • A11-B3-C31 A11-B3-C32 A12-B3-C3; A12-B3-C4; A12-B3-C5; A12-B3-C6;
  • A12-B3-C31 A12-B3-C32 A13-B3-C3; A13-B3-C4; A13-B3-C5; A13-B3-C6:
  • A13-B3-C31 A13-B3-C32 A14-B3-C3; A14-B3-C4; A14-B3-C5; A14-B3-C6;
  • A14-B3-C31 A14-B3-C32 A15-B3-C3; A15-B3-C4; A15-B3-C5; A15-B3-C6;
  • A15-B3-C31 A15-B3-C32 A16-B3-C3; A16-B3-C4; A16-B3-C5; A16-B3-C6:
  • A16-B3-C31 A16-B3-C32 A17-B3-C3; A17-B3-C4; A17-B3-C5; A17-B3-C6;
  • A17-B3-C31 A17-B3-C32 A18-B3-C3; A18-B3-C4; A18-B3-C5; A18-B3-C6;
  • A18-B3-C31 A18-B3-C32 A19-B3-C3; A19-B3-C4; A19-B3-C5; A19-B3-C6;
  • A19-B3-C31 A19-B3-C32 A20-B3-C3; A20-B3-C4; A20-B3-C5; A20-B3-C6; A20-B3-C7; A20-B3-C8; A20-B3-C9; A20-B3-C10 A20-B3-C11 A20-B3 -C12
  • A26-B3-C31 A26-B3-C32; A27-B3-C3; A27-B3-C4; A27-B3-C5; A27-B3 C6;
  • A27-B3-C31 A27-B3-C32; A28-B3-C3; A28-B3-C4; A28-B3-C5; A28-B3- C6;
  • A30-B3-C31 A30-B3-C32 A31-B3-C3; A31-B3-C4; A31-B3-C5; A31-B3-C6;
  • A31-B3-C31 A31-B3-C32 A32-B3-C3; A32-B3-C4; A32-B3-C5; A32-B3-C6;
  • A32-B3-C31 A32-B3-C32 A33-B3-C3; A33-B3-C4; A33-B3-C5; A33-B3-C6;
  • A33-B3-C31 A33-B3-C32 A34-B3-C3; A34-B3-C4; A34-B3-C5; A34-B3-C6;
  • A34-B3-C31 A34-B3-C32 A35-B3-C3; A35-B3-C4; A35-B3-C5; A35-B3-C6;
  • A35-B3-C31 A35-B3-C32 A36-B3-C3; A36-B3-C4; A36-B3-C5; A36-B3-C6;
  • A36-B3-C31 A36-B3-C32 A1-B4-C3; A1-B4-C4; A1-B4-C5; A1-B4-C6;
  • A1-B4-C13 A1-B4-C14 A1-B4-C15 A1-B4-C16 A1-B4-C17; A1-B4-C18
  • A1-B4-C31 A1-B4-C32 A2-B4-C3; A2-B4-C4; A2-B4-C5; A2-B4-C6;
  • A2-B4-C31 A2-B4-C32 A3-B4-C3; A3-B4-C4; A3-B4-C5; A3-B4-C6;
  • A3-B4-C31 A3-B4-C32 A4-B4-C3; A4-B4-C4; A4-B4-C5; A4-B4-C6;
  • A5-B4-C31 A5-B4-C32 A6-B4-C3; A6-B4-C4; A6-B4-C5; A6-B4-C6;
  • A6-B4-C31 A6-B4-C32 A7-B4-C3; A7-B4-C4; A7-B4-C5; A7-B4-C6;
  • A7-B4-C31 A7-B4-C32 A8-B4-C3; A8-B4-C4; A8-B4-C5; A8-B4-C6;
  • A8-B4-C31 A8-B4-C32 A9-B4-C3; A9-B4-C4; A9-B4-C5; A9-B4-C6;
  • A10-B4-C31 A10-B4-C32 A11-B4-C3; A11-B4-C4; A11-B4-C5; A11-B4-C6;
  • A11-B4-C31 A11-B4-C32 A12-B4-C3; A12-B4-C4; A12-B4-C5; A12-B4-C6;
  • A12-B4-C31 A12-B4-C32 A13-B4-C3; A13-B4-C4; A13-B4-C5; A13-B4-C6;
  • A13-B4-C31 A13-B4-C32 A14-B4-C3; A14-B4-C4; A14-B4-C5; A14-B4-C6;
  • A14-B4-C31 A14-B4-C32 A15-B4-C3; A15-B4-C4; A15-B4-C5; A15-B4-C6;
  • A16-B4-C31 A16-B4-C32 A17-B4-C3; A17-B4-C4; A17-B4-C5; A17-B4-C6:
  • A17-B4-C31 A17-B4-C32 A18-B4-C3; A18-B4-C4; A18-B4-C5; A18-B4-C6;
  • A18-B4-C31 A18-B4-C32 A19-B4-C3; A19-B4-C4; A19-B4-C5; A19-B4-C6;
  • A19-B4-C31 A19-B4-C32 A20-B4-C3; A20-B4-C4; A20-B4-C5; A20-B4-C6;
  • A20-B4-C31 A20-B4-C32 A21-B4-C3; A21-B4-C4; A21-B4-C5; A21-B4-C6:
  • A21-B4-C31 A21-B4-C32 A22-B4-C3; A22-B4-C4; A22-B4-C5; A22-B4-C6;
  • A22-B4-C31 A22-B4-C32 A23-B4-C3; A23-B4-C4; A23-B4-C5; A23-B4-C6;
  • A23-B4-C31 A23-B4-C32 A24-B4-C3; A24-B4-C4; A24-B4-C5; A24-B4-C6;
  • A24-B4-C31 A24-B4-C32 A25-B4-C3; A25-B4-C4; A25-B4-C5; A25-B4-C6;
  • A25-B4-C31 A25-B4-C32 A26-B4-C3; A26-B4-C4; A26-B4-C5; A26-B4-C6;
  • A26-B4-C25 A26-B4-C26; A26-B4-C27; A26-B4-C28 A26-B4 C29; A26-B4 C30
  • A26-B4-C31 A26-B4-C32; A27-B4-C3; A27-B4-C4; A27-B4 C5: A27-B4 C6;
  • A27-B4-C13 A27-B4-C14; A27-B4-C15 A27-B4-C16 A27-B4 C17; A27-B4 C18
  • A27-B4-C31 A27-B4-C32; A28-B4-C3; A28-B4-C4; A28-B4 C5; A28-B4 C6;
  • A28-B4-C31 A28-B4-C32; A29-B4-C3; A29-B4-C4; A29-B4 C5: A29-B4 C6;
  • A29-B4-C31 A29-B4-C32; A30-B4-C3; A30-B4-C4; A30-B4 C5: A30-B4 C6;
  • A30-B4-C31 A30-B4-C32; A31-B4-C3; A31-B4-C4; A31-B4 C5; A31-B4 C6;
  • A32-B4-C31 A32-B4-C32; A33-B4-C3; A33-B4-C4; A33-B4 C5: A33-B4 C6;
  • A33-B4-C13 A33-B4-C14; A33-B4-C15 A33-B4-C16 A33-B4 C17; A33-B4 C18
  • A33-B4-C31 A33-B4-C32; A34-B4-C3; A34-B4-C4; A34-B4 C5: A34-B4 C6;
  • A34-B4-C13 A34-B4-C14; A34-B4-C15 A34-B4-C16 A34-B4- C17; A34-B4 C18
  • A34-B4-C31 A34-B4-C32; A35-B4-C3; A35-B4-C4; A35-B4- C5; A35-B4 C6;
  • A35-B4-C31 A35-B4-C32; A36-B4-C3; A36-B4-C4; A36-B4- C5; A36-B4- C6;

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés physiologiquement actifs représentés par la formule générale (I) dans laquelle R1 représente aryle, hétéroaryle ou un groupe R?3-L2-Ar1-L3-; R2¿ représente hydrogène ou alkyle inférieur; R3 représente aryle ou hétéroaryle; et Ar1 représente un système annulaire bicyclique de 8 à 10 chaînons, saturé, partiellement saturé ou entièrement saturé, éventuellement substitué, contenant au moins un hétéroatome sélectionné parmi O, S ou N; Y est carboxy ou un bioisostère acide. L'invention concerne également les N-oxydes ou promédicaments associés à ces composés, et les sels et solvates acceptables d'un point de vue pharmaceutique de ces composés et les N-oxydes ou promédicaments correspondants. Ces composés possèdent des propriétés pharmaceutiques précieuses, en particulier la capacité de réguler l'interaction de VCAM-1 et de la fibronectine avec l'intégrine VLA-4(α4β1).
PCT/GB2001/000844 2000-02-28 2001-02-28 Derives d'indane WO2001064659A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL15072401A IL150724A0 (en) 2000-02-28 2001-02-28 Indane derivatives
DE60105771T DE60105771T2 (de) 2000-02-28 2001-02-28 Indanderivate und ihre verwendung als zelladhäsionsinihibitoren
AT01907923T ATE277023T1 (de) 2000-02-28 2001-02-28 Indanderivate und ihre verwendung als zelladhäsionsinihibitoren
CA2401441A CA2401441C (fr) 2000-02-28 2001-02-28 Derives d'indane
EP01907923A EP1259495B1 (fr) 2000-02-28 2001-02-28 Derives d'indane et leur utilisation comme inhibiteurs d'adhesion cellulaire
AU35790/01A AU3579001A (en) 2000-02-28 2001-02-28 Indane derivatives and their use as cell adhesion inhibitors
MXPA02008375A MXPA02008375A (es) 2000-02-28 2001-02-28 Derivados de indano.
JP2001563500A JP5021133B2 (ja) 2000-02-28 2001-02-28 インダン誘導体および細胞接着抑制物質としてのそれらの使用
US10/229,592 US6762199B2 (en) 2000-02-28 2002-08-28 Indane derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0004686.2 2000-02-28
GBGB0004686.2A GB0004686D0 (en) 2000-02-28 2000-02-28 Chemical compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/229,592 Continuation US6762199B2 (en) 2000-02-28 2002-08-28 Indane derivatives

Publications (2)

Publication Number Publication Date
WO2001064659A2 true WO2001064659A2 (fr) 2001-09-07
WO2001064659A3 WO2001064659A3 (fr) 2001-12-27

Family

ID=9886551

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/000844 WO2001064659A2 (fr) 2000-02-28 2001-02-28 Derives d'indane

Country Status (13)

Country Link
US (1) US6762199B2 (fr)
EP (1) EP1259495B1 (fr)
JP (1) JP5021133B2 (fr)
AR (1) AR027578A1 (fr)
AT (1) ATE277023T1 (fr)
AU (1) AU3579001A (fr)
CA (1) CA2401441C (fr)
DE (1) DE60105771T2 (fr)
ES (1) ES2227137T3 (fr)
GB (1) GB0004686D0 (fr)
IL (1) IL150724A0 (fr)
MX (1) MXPA02008375A (fr)
WO (1) WO2001064659A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030889A1 (fr) * 2001-10-03 2003-04-17 Bayer Healthcare Ag Acides para-amino benzoiques utilises en tant qu'antagonistes des integrines
US7157487B2 (en) 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
US7691894B2 (en) 2003-07-24 2010-04-06 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8005919B2 (en) 2002-11-18 2011-08-23 Aol Inc. Host-based intelligent results related to a character stream
CA2506585A1 (fr) 2002-11-18 2004-06-03 Valerie Kucharewski Listes de personnes
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体
WO2012074980A2 (fr) * 2010-12-01 2012-06-07 Dara Biosciences, Inc. Procédés de traitement ou de prévention de troubles auto-immunitaires et de troubles du foie à l'aide de dérivés acides indane acétiques
AU2021267373A1 (en) 2020-05-06 2022-12-08 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2023086319A1 (fr) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-hetero-aryloxy-benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005224A2 (fr) * 1998-07-23 2000-02-03 Astrazeneca Ab Composés chimiques
WO2000005223A2 (fr) * 1998-07-23 2000-02-03 Astrazeneca Ab Composes chimiques
WO2000049005A1 (fr) * 1999-02-16 2000-08-24 Aventis Pharma Limited Composes bicycliques et leur utilisation comme ligands du recepteur de l'integrine
WO2000068213A1 (fr) * 1999-05-05 2000-11-16 Aventis Pharma Limited Composes bicycliques substitues

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2041594A5 (fr) * 1969-04-30 1971-01-29 Expanscience
US4331692A (en) * 1971-07-23 1982-05-25 Ulla Drevici Cocoa fruits and products
GB1541463A (en) * 1975-10-11 1979-02-28 Lion Dentifrice Co Ltd Process for prparing a multiple emulsion having a dispersing form of water-phase/oil-phase/water-phase
US4151304A (en) * 1976-11-05 1979-04-24 Lever Brothers Company Method and composition for moisturizing the skin
FR2380775A1 (fr) * 1977-02-22 1978-09-15 Sederma Sarl Composition " apres-epilation " favorisant un ralentissement progressif de la repousse des poils
US4190671A (en) * 1977-03-17 1980-02-26 Biorex Laboratories Limited Chalcone derivatives
US4279930A (en) * 1978-10-10 1981-07-21 The Upjohn Company Process for treating inflammation
DE3040246C2 (de) * 1979-10-29 1985-01-10 Osaka Chemical Laboratory Co., Ltd., Osaka Sojasaponine A↓1↓ und A↓2↓ und ihre Verwendung
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
US4272544A (en) * 1980-08-20 1981-06-09 Eli Lilly And Company Skin cell renewal regime
US4278570A (en) * 1980-08-20 1981-07-14 Eli Lilly And Company Cosmetic cleanser formulation
DE3109420A1 (de) * 1981-03-12 1982-09-23 Kastell, Wolfgang, 2000 Hamburg Mittel zum anhalten des haarausfalls und zum foerdern des haarwuchses
FR2509988B1 (fr) * 1981-07-23 1986-05-30 Oreal Melange d'huiles vegetales a base d'huile de jojoba comme agent de stabilisation a l'oxydation et compositions cosmetiques le contenant
DE3129867A1 (de) * 1981-07-29 1983-02-17 Henkel Kgaa "ungesaettigte arylketone als antiseborrhoische zusaetze fuer kosmetische mittel"
US4382960A (en) * 1981-08-03 1983-05-10 Eli Lilly And Company Cosmetic cleanser formulation
US4368187A (en) * 1981-08-03 1983-01-11 Eli Lilly And Company Sensitive-skin care regime
US4578267A (en) * 1981-09-15 1986-03-25 Morton Thiokol, Inc. Skin conditioning polymer containing alkoxylated nitrogen salts of sulfonic acid
US4462981A (en) * 1982-12-10 1984-07-31 Creative Products Resource, Associates Ltd. Cosmetic applicator useful for skin moisturizing and deodorizing
US5192332A (en) * 1983-10-14 1993-03-09 L'oreal Cosmetic temporary coloring compositions containing protein derivatives
JPS60109544A (ja) * 1983-11-17 1985-06-15 Kao Corp 新規カルコン誘導体及びこれを含有する紫外線吸収剤
FR2580478B1 (fr) * 1985-04-17 1989-05-12 Christian Chapoton Dispositif de traitement capillaire liberant une substance active et procede de fabrication
US4760096A (en) * 1985-09-27 1988-07-26 Schering Corporation Moisturizing skin preparation
US4847267A (en) * 1986-03-17 1989-07-11 Charles Of The Ritz Group Ltd. Skin treatment composition and method
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
US4824662A (en) * 1987-06-15 1989-04-25 Vi-Jon Laboratories, Inc. Nail polish remover
IT1222012B (it) * 1987-07-10 1990-08-31 Indena Spa Composizioni farmaceutiche e cosmetiche contenenti complessi di flavonolignani con fosfolipidi
IT1223290B (it) * 1987-07-27 1990-09-19 Indena Spa Acidi poliinsaturi ad azione vasocinetica e relative formulazioni farmaceutiche e cosmetiche
LU86997A1 (fr) * 1987-09-21 1989-04-06 Oreal Composition cosmetique filtrante photostable contenant de la bixine associee a un filtre uv liposoluble et son utilisation pour la protection de l'epiderme humain contre les radiations ultraviolettes
DE3784245T2 (de) * 1987-11-24 1993-09-02 Agfa Gevaert Nv Magnetische traegerteilchen.
CH676470A5 (fr) * 1988-02-03 1991-01-31 Nestle Sa
DE3814839A1 (de) * 1988-05-02 1989-11-16 Henkel Kgaa Haarbehandlungsmittel mit natuerlichen inhaltsstoffen
US4906457A (en) * 1988-09-06 1990-03-06 Washington State University Research Foundation, Inc. Compositions and methods for reducing the risk of sunlight and ultraviolet induced skin cancer
US4851214A (en) * 1988-09-07 1989-07-25 Ici Americas Inc. Deodorants containing N-soya-N-ethyl morpholinium ethosulfate
US4943462A (en) * 1989-01-17 1990-07-24 Semex Medical, Inc. Nail treatment device
US5116605A (en) * 1989-03-09 1992-05-26 Alt John P Composition and skin treatment method therewith for mitigating acne and male-pattern baldness
US5194252A (en) * 1989-07-27 1993-03-16 Vijon Laboratories, Inc. Moisture retaining aftershave
US5032400A (en) * 1989-11-02 1991-07-16 Erie Laboratories Shark liver oil and garlic oil topical analgesic
US5622690A (en) * 1990-04-05 1997-04-22 Nurture, Inc. Seed-derived proteinaceous compositions for reduction of sunburn cell formation
FR2663633B1 (fr) * 1990-06-22 1994-06-17 Adir Nouvelles chalcones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5231090A (en) * 1990-07-30 1993-07-27 University Of Miami Treatment for hypercholesterolemia
US5407675A (en) * 1990-08-10 1995-04-18 Etemad-Moghadam; Parviz Method and composition for use on the scalp and eyebrow region of a subject
CA2049728A1 (fr) * 1990-08-24 1992-02-25 Kenji Kitamura Composition de lavage capable de prevenir et d'ameliorer les irritations de la peau
US5217717A (en) * 1990-09-06 1993-06-08 Central Soya Company, Inc. Method of making soybean Bowman-Birk inhibitor concentrate and use of same as a human cancer preventative and therapy
CA2073353C (fr) * 1990-11-14 2003-10-28 Alexandre Zysman Composes amphiphiles non-ioniques derives du glycerol, leur procede de preparation, composes intermediaires correspondants et compositions contenant lesdits composes
US5110603A (en) * 1991-01-31 1992-05-05 Kao Corporation Bathing preparation for colloidal material
US5188823A (en) * 1991-02-07 1993-02-23 Stepan Company Antiperspirant formulations
US5498420A (en) * 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
US5229104A (en) * 1991-04-29 1993-07-20 Richardson-Vicks Inc. Artificial tanning compositions containing positively charged paucilamellar vesicles
EP0514576A1 (fr) * 1991-05-24 1992-11-25 Societe Des Produits Nestle S.A. Mélange antioxydant liposoluble
US5310734A (en) * 1991-07-05 1994-05-10 Rhone-Poulenc Rorer Phospholipid composition
EP0532465B1 (fr) * 1991-09-13 2002-07-10 Pentapharm A.G. Fraction protéinique pour les soins cosmétiques et dermatologiques de la peau
JPH07501540A (ja) * 1991-11-25 1995-02-16 リチャードソン、ビックス、インコーポレーテッド 皮膚シワ及び／又は皮膚萎縮を調節するための組成物
WO1993010756A1 (fr) * 1991-11-25 1993-06-10 Richardson-Vicks, Inc. Emploi d'acide salicylique contre les rides et/ou l'atrophie cutanee
FR2687314A1 (fr) * 1992-02-18 1993-08-20 Oreal Dispersion de vesicules lipidiques, composition cosmetique et/ou pharmaceutique la contenant et procede de preparation de ladite dispersion.
US5766628A (en) * 1992-02-24 1998-06-16 Merz + Co. Gmbh & Co. Bath and shower composition having vesicle-forming properties and method for the production and use thereof
US5393519A (en) * 1992-03-27 1995-02-28 Helene Curtis, Inc. Shampoo compositions
DE4226173A1 (de) * 1992-08-07 1994-02-10 Solvay Fluor & Derivate Badezusatzpräparat
FR2694934B1 (fr) * 1992-08-24 1994-11-10 Oreal Composition pour le traitement de l'acné contenant un dérivé d'acide salicylique et dérivés d'acide salicylique.
US6048520A (en) * 1992-09-24 2000-04-11 Helene Curtis, Inc. Clear leave-on hair treatment composition and method
US5753612A (en) * 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
CA2119064A1 (fr) * 1993-03-17 1994-09-18 Richard A. Berg Systeme d'analyse dermo-epidermique in vitro
US5276058A (en) * 1993-06-09 1994-01-04 Nippon Hypox Laboratories Incorporated 3,4-dihydroxychalcone derivatives
FR2710264B1 (fr) * 1993-09-21 1995-12-08 Rocher Yves Biolog Vegetale Utilisation pour le traitement des peaux mixtes d'une quantité efficace de substances actives.
DE4343431C1 (de) * 1993-12-18 1995-05-04 Henkel Kgaa Kosmetische und/oder pharamzeutische Zubereitungen
FR2714596B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition cosmétique pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation.
US6013255A (en) * 1994-04-18 2000-01-11 Gist-Brocades B.V. Stable water-in-oil emulsions
GB9414045D0 (en) * 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
DE4444238A1 (de) * 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
US5523308A (en) * 1995-06-07 1996-06-04 Costanzo; Michael J. Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5639785A (en) * 1995-06-07 1997-06-17 Global Pharma, Ltd. Methods for the treatment of baldness and gray hair using isoflavonoid derivatives
US6013250A (en) * 1995-06-28 2000-01-11 L'oreal S. A. Composition for treating hair against chemical and photo damage
US6063398A (en) * 1995-09-20 2000-05-16 L'oreal Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent
US5885593A (en) * 1995-09-28 1999-03-23 The Andrew Jergens Company Skin care composition including cyclodextrin materials and method for treating skin therewith
US6019962A (en) * 1995-11-07 2000-02-01 The Procter & Gamble Co. Compositions and methods for improving cosmetic products
DE69611754T2 (de) * 1995-11-24 2001-05-23 Mitsui Chemicals Inc Hydrochalconderivate, sie enthaltende kosmetische zusammensetzungen, und verfahren zur herstellung von beiden
US5643587A (en) * 1996-02-15 1997-07-01 Avon Products, Inc. Composition and method for under-eye skin lightening
FR2747568B1 (fr) * 1996-04-17 1999-09-17 Oreal Utilisation d'au moins un inhibiteur de lipoxygenase et d'au moins un inhibiteur de cyclo-oxygenase pour modifier la pousse des poils et/ou des cheveux
IL119535A (en) * 1996-10-31 2001-01-11 Chajuss Daniel Soy molasses and modified soy molasses for topical application
FR2757767B1 (fr) * 1996-12-27 1999-02-05 Oreal Composition topique contenant au moins une proteine d'origine vegetale et/ou une proteine d'origine animale et une poly(acide 2-acrylamido 2-methylpropane sulfonique) reticule
US5863546A (en) * 1997-03-02 1999-01-26 Swinehart; James M Cosmetic composition
US5885600A (en) * 1997-04-01 1999-03-23 Burlington Bio-Medical & Scientific Corp. Natural insect repellent formula and method of making same
US5885596A (en) * 1997-07-23 1999-03-23 Bristol-Myers Squibb Company Methods and compositions for fine lines and/or wrinkles
US6017893A (en) * 1997-08-29 2000-01-25 Natures Sunshine Products, Inc. Use of isoflavones to prevent hair loss and preserve the integrity of existing hair
US5928658A (en) * 1997-12-05 1999-07-27 U.S. Cosmetics Oil-free wax-free solid cosmetic composition
FR2772613B1 (fr) * 1997-12-19 2003-05-09 Oreal Utilisation du phloroglucinol dans une composition cosmetique
US6030931A (en) * 1998-02-03 2000-02-29 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Foaming cleansing skin product
US5928889A (en) * 1998-02-13 1999-07-27 S.C. Johnson & Son, Inc. Protocol for simulated natural biofilm formation
KR20010041938A (ko) * 1998-03-16 2001-05-25 데이비드 엠 모이어 피부 외형을 조절하는 방법
CO5090829A1 (es) * 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005224A2 (fr) * 1998-07-23 2000-02-03 Astrazeneca Ab Composés chimiques
WO2000005223A2 (fr) * 1998-07-23 2000-02-03 Astrazeneca Ab Composes chimiques
WO2000049005A1 (fr) * 1999-02-16 2000-08-24 Aventis Pharma Limited Composes bicycliques et leur utilisation comme ligands du recepteur de l'integrine
WO2000068213A1 (fr) * 1999-05-05 2000-11-16 Aventis Pharma Limited Composes bicycliques substitues

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157487B2 (en) 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
WO2003030889A1 (fr) * 2001-10-03 2003-04-17 Bayer Healthcare Ag Acides para-amino benzoiques utilises en tant qu'antagonistes des integrines
US7691894B2 (en) 2003-07-24 2010-04-06 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
US7893279B2 (en) 2003-07-24 2011-02-22 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound

Also Published As

Publication number Publication date
DE60105771T2 (de) 2006-02-16
DE60105771D1 (de) 2004-10-28
MXPA02008375A (es) 2002-12-13
JP5021133B2 (ja) 2012-09-05
CA2401441A1 (fr) 2001-09-07
AU3579001A (en) 2001-09-12
GB0004686D0 (en) 2000-04-19
US20030199564A1 (en) 2003-10-23
ES2227137T3 (es) 2005-04-01
ATE277023T1 (de) 2004-10-15
IL150724A0 (en) 2003-02-12
CA2401441C (fr) 2011-11-15
WO2001064659A3 (fr) 2001-12-27
EP1259495B1 (fr) 2004-09-22
EP1259495A2 (fr) 2002-11-27
US6762199B2 (en) 2004-07-13
JP2003525281A (ja) 2003-08-26
AR027578A1 (es) 2003-04-02

Similar Documents

Publication Publication Date Title
EP1183254B1 (fr) Composes d'heteroaryle bicyclique substitue utilises comme antagonistes de l'integrine
EP1153017B1 (fr) Composes bicycliques et leur utilisation comme ligands du recepteur de l'integrine
AU2002302783B2 (en) Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases
EP1177181B1 (fr) Composes bicycliques substitues
WO2000068223A1 (fr) Urees en tant que modulateurs de l'adhesion cellulaire
AU2002302783A1 (en) Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases
CA2427750C (fr) Acides alcanoiqies substitues
EP1259495B1 (fr) Derives d'indane et leur utilisation comme inhibiteurs d'adhesion cellulaire
US6632814B1 (en) Dihydro-benzo(1,4)oxazines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001907923

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 35790/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 150724

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2001 563500

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/008375

Country of ref document: MX

Ref document number: 2401441

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10229592

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001907923

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001907923

Country of ref document: EP